The pharmaceutical industry is racing to meet demand for GLP-1 weight-loss drugs, such as Ozempic and Mounjaro, a market that JPMorgan forecasts will reach $200 billion by 2030. Meanwhile, the antibiotics that keep surgery, chemotherapy and childbirth safe are losing effectiveness; approximately 5 million deaths were associated with bacterial antimicrobial resistance in 2019 alone, and the companies developing replacements keep going bankrupt. Antibiotic companies raised just $160 million in venture capital in 2020, while oncology companies raised $7 billion.
The trajectory is dire. A landmark Lancet study forecasts 39.1 million deaths directly caused by drug-resistant infections between 2025 and 2050, rounding to three infections every minute. By 2050, nearly 2 million could die annually from untreatable infections, an almost 70% increase from 2022. This isn’t hypothetical: The World Health Organization reported in 2025 that 1 in 6 bacterial infections worldwide already resist standard treatment. In the United States, carbapenem-resistant infections surged 69% in a single year, with the especially infectious strains spiking 461%. These are everyday infections — urinary tract infections, pneumonia and post-surgical complications — becoming untreatable.
The pipeline meant to fight back is collapsing. The WHO found just 90 antibiotics in development in 2025, down from 97 two years prior, with only 15 classified as innovative. A separate industry analysis found just 60 projects in 2026 remain among large pharma companies, down from 92 in 2021. New antibiotics are used sparingly by design, making them unprofitable, so most major companies have left the space entirely.
The World Bank estimates antimicrobial resistance could cost $1 trillion in additional healthcare expenses by 2050 and $1 trillion to $3.4 trillion in annual gross domestic product losses by 2030. The market won’t fix this — antibiotics will never compete with GLP-1s for investor attention. Until governments step in with mandatory stewardship, funded development incentives and global surveillance, we are sleepwalking toward a post-antibiotic era where routine medicine becomes a gamble.
